Snapshot · Merck & Co., Inc. (MRK)

Data as of 2026-10-18T09:29:30.451Z

Fundamentals check

Market cap

$360.1B

P/E (TTM)

115.8

Gross margin

75.4%

Net margin

4.8%

ROE

6.6%

R&D / revenue

42.7%

Dividend yield

2.3%

FCF yield

4.5%

Latest dividend: $0.85/share (ex-date 2026-09-15, quarterly)

Summary

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

How it makes money

Revenue mix, latest fiscal year

• Pharmaceutical segment89.4%
• Animal Health segment9.8%
• Other Segments0.8%

Recent Events

• 2026-10-14T13:24:20.000Zneutral

  Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

  与公司新产品制造效率相关的采访，可能对市场情绪产生影响，但非确定性因果关系。

  Source: cnbc.com

• 2026-10-14T11:51:08.000Zneutral

  Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

  可能与公司季度盈利前景相关的报道，但不构成确定性结论，需关注后续业绩披露。

  Source: zacks.com

• 2026-10-14T00:00:00.000Zpositive

  Price move: MRK rose 3.8%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-12T12:21:52.000Znegative

  Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns

  或有助于理解分析师对药物销售前景的下调，但尚需更多试验数据确认影响，存在不确定性。

  Source: proactiveinvestors.com

• 2026-08-19T00:00:00.000Zpositive

  Price move: MRK rose 12.6%

  MRK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $155.41 from 22 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-13SellGuindo Chirfi(officer: EVP, Access, Policy & Comms)10,000 shares
• 2026-08-12SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)600 shares
• 2026-08-12SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)11,099 shares
• 2026-08-12SellZachary Jennifer(officer: EVP, General Counsel)80,315 shares
• 2026-08-11SellDeLuca Richard R.(officer: EVP&Pres, Merck Animal Heallth)5,427 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。